EP3500299

COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCER

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    18.8.2017
  • :
    13.12.2023
  • :
    17841107.0
  • :
    17.8.2037
  • :
    COMBINATION OF ZANUBRUTINIB WITH AN ANTI-CD20 OR AN ANTI-PD-1 ANTIBODY FOR USE IN TREATING CANCER

18.8.2017
13.12.2023
  • :
    Beigene Switzerland GmbH
  • :
    Aeschengraben 27, 4051 Basel, CH
  • :
    HU, Nan
  • :
    Beijing 102206, CN
  • :
    WANG, Lai
  • :
    Beijing 102206, CN
  • :
    SONG, Jing
  • :
    Beijing 102206, CN
  • :
    ZHANG, Tong
  • :
    Beijing 102206, CN
  • :
    LI, Kang
  • :
    Beijing 102206, CN
  • :
    LUO, Lusong
  • :
    Beijing 102206, CN
  • :
    WEI, Min
  • :
    Beijing 102206, CN
  • :
    WANG, Zhiwei
  • :
    Beijing 102206, CN
  • :
    GUO, Yunhang
  • :
    Beijing 102206, CN
  • :
    PCT/CN2016/096082
  • :
    19.8.2016
  • :
    WO
  • :
    CN2017098023
  • :
    18.8.2017
  • :
    A61K 39/395, A61K 31/519, A61K 31/4162, A61P 35/00, C07K 16/28